Literature DB >> 240884

Interaction of C3b, B, and D in the alternative pathway of complement activation.

A Nicholson, V Brade, H U Schorlemmer, R Burger, D Bitter-Suermann, U Hadding.   

Abstract

The interaction of ZXd2, an insoluble intermediate of the alternative pathway on zymosan (Z5), with factor B and the enzyme D proceeds in a two-step reaction: 1) B binds in the presence of Mg++ to ZXd2 to form the intermediate ZXd2B, 2) B bound to ZXd2 is subsequently activated enzymatically by D to yield the complex ZXd2B which cleaves C3. Evidence was obtained that C3b, which is present on ZXd2, is required for ZXd2B formation. Studies of the functional role of C3b for ZXd2B formation revealed that C3b is involved in the first reaction step i.e., binding of B to ZXd2 to yield ZXd2B. Formation of ZXd2B is inhibited by pretreatment of ZXd2 with either anti-C3 Fab or with C3b-INA. Low ionic strength of about 2 mS was found to favor the interaction of the C3b with B. Mg++ concentrations from 1 to 31 mM as well as variation of pH in the range from 6.2 to 8.5 did not greatly influence the reaction of B with ZXd2. For the enzymatic activation of B only C3b on ZXd2 and factor D are required. This is concluded from the finding that fluid phase C3b is sufficient for the activation of B in the presence of D. This does not exclude the fact that other proteins present on ZXd2 may help to stabilize the intermediate ZXd2B or the enzymatically active complex AXd2B, or both of them.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 240884

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro.

Authors:  C Bentley; W Fries; V Brade
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

2.  Changes in humoral components of host defense following burn trauma.

Authors:  A B Bjornson; W A Altemeier; H S Bjornson
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

3.  Effects of activated complement components on enzyme secretion by macrophages.

Authors:  H U Schorlemmer; A C Allison
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

4.  Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins.

Authors:  Hemendra Singh Panwar; Hina Ojha; Payel Ghosh; Sagar H Barage; Sunil Raut; Arvind Sahu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

5.  Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  C J Parker; P J Baker; W F Rosse
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

6.  Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.

Authors:  J Ferluga; H U Schorlemmer; L C Baptista; A C Allison
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

7.  Insoluble polyanions as activators of both pathways of complement.

Authors:  R Burger; D Bitter-Suermann; M Loos; U Hadding
Journal:  Immunology       Date:  1977-12       Impact factor: 7.397

8.  Solid phase activation of alternative pathway of complement by beta-1,3-glucans and its possible role for tumour regressing activity.

Authors:  J Hamuro; U Hadding; D Bitter-Suermann
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

9.  Host defense against opportunist microorganisms following trauma. I. Studies to determine the association between changes in humoral components of host defense and septicemia in burned patients.

Authors:  A B Bjornson; W A Altemeier; H S Bjornson; T Tang; M L Iserson
Journal:  Ann Surg       Date:  1978-07       Impact factor: 12.969

10.  Macrophage responses to mouldy hay dust, Micropolyspora faeni and zymosan, activators of complement by the alternative pathway.

Authors:  H U Schorlemmer; J H Edwards; P Davies; A C Allison
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.